Anti-inflammatory activity of roflumilast: Study on the efficacy of oral roflumilast (500 μg/d) over 4 weeks on sputum eosinophils in patients with asthma. A double-blind randomized placebo-controlled parallel group study

Study identifier:BY217/FHP031

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

42

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Mar 2001
Primary Completion Date: -
Study Completion Date: 01 Sept 2004

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Sponsors

Takeda

Collaborators

-

Inclusion and exclusion criteria